We are live on ! Find out more
ASMB icon

Assembly Biosciences

69 hedge funds and large institutions have $467M invested in Assembly Biosciences in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,114% more call options, than puts

Call options by funds: $85K | Put options by funds: $7K

175% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 8

77% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 13

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

44% more capital invested

Capital invested by funds: $325M → $467M (+$142M)

21% more funds holding

Funds holding: 5769 (+12)

75.93% less ownership

Funds ownership: 162.7%86.77% (-76%)

Holders
69
Holders Change
+12
Holders Change %
+21.05%
% of All Funds
0.84%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
22
Increased
23
Reduced
13
Closed
8
Calls
$85K
Puts
$7K
Net Calls
+$78K
Net Calls Change
-$11.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
76
Wells Fargo
California
-$3.71K -145 Closed
SS
77
SBI Securities
Japan
-$1.74K -68 Closed

ASMB Hedge Fund Activity: Q4 2025 in Review

69 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2025, worth a combined $467M — up 44% from $325M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ASMB positions and 8 closed out — a net gain of 14 holders — while 23 added to existing stakes and 13 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $21.4M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $11.7M sold.

  • 69 institutional investors held Assembly Biosciences (ASMB) as of Q4 2025, up from 57 in Q3 2025.
  • Funds reported $467M of Assembly Biosciences stock for Q4 2025, up 44% quarter-over-quarter.
  • 22 funds opened new Assembly Biosciences positions in Q4 2025 and 8 closed out, a net change of +14 holders.
  • The largest Assembly Biosciences buyer in Q4 2025 was Paradigm Biocapital Advisors, an estimated $21.4M added.
  • The largest Assembly Biosciences seller in Q4 2025 was Frazier Life Sciences Management, an estimated $11.7M sold.

Based on aggregated 13F filings for Q4 2025.